Clinical and Translational Research in Cancer
Lines of Research
01.Clinical-translational research in breast, prostate, gynecological, digestive, and germ cell cancers
02.Translational research in the identification of epigenetic/genetic markers in early stages of cancer
03.Research on the use of new diagnostic techniques (liquid biopsy, etc.) and markers
04.Research on the relationship between the microbiota and cancer
05.Research on real-world data real world data
- Research projects
- Clinical studies
- Scientific Publications
- Technological Offers
- Industrial property records
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
A retrospective, observational, multicenter study of treatment with sacituzumab govitecan in patients with locally advanced and/or metastatic triple-negative breast cancer within routine clinical practice in Spain (TROPSPAIN)
FRANCISCO JAVIER PASCUAL LOPEZ – ESTUDIO OBSERVACIONAL CON MEDICAMENTOS – No aplica – GILEAD SCIENCES, S.L.U
A Phase IIIB study to evaluate the useof durvalumab in combination with platinun-bas chemotherpy followed by urvalumab with olaparib as first-line tratment in Patientsw Newly Diagnosed pMMR Advanced or Recurret Endometrial Cancer in Spain.
MARIA JOSE BERMEJO PEREZ – ENSAYO CLINICO CON MEDICAMENTOS – III – APICES SOLUCIONES S.L.
A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292-D361DC00001)
MARIA EMILIA DOMINGUEZ RECIO – ENSAYO CLINICO CON MEDICAMENTOS – III – ASTRAZENECA AB
A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies
JAVIER GARCÍA CORBACHO – ENSAYO CLINICO CON MEDICAMENTOS – I – INCYTE CORPORATION
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors
JAVIER GARCÍA CORBACHO – ENSAYO CLINICO COMERCIAL – I – ABBVIE DEUTSCHLAND GMBH & CON K. G
A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors
JAVIER GARCÍA CORBACHO – ENSAYO CLINICO CON MEDICAMENTOS – I – DEBIOPHARM INTERNATIONAL S.A.
A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)
LAURA MEDINA RODRÍGUEZ – ENSAYO CLINICO COMERCIAL – I – PRECISION FOR MEDICINE, LLC
2023-12144 Estudio observacional, internacional, retrospectivo de revisión de historiasclínicas, para describir las características, patrones de tratamiento y resultados clínicos en los pacientestratados con selpercatinib dentro de un Programa de Acceso Temprano en España y Portugal (EstudioSELPIBER).
ANDRES MESAS RUIZ – ESTUDIO OBSERVACIONAL CON MEDICAMENTOS – No aplica – LILLY, S.A.
“Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de olaparib frente a placebo como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2, que han finalizado el tratamiento local y la quimioterapia neoadyuvante o adyuvante”. Estudio OLYMPIA.
ANTONIA MÁRQUEZ ARAGONÉS – ENSAYO CLINICO COMERCIAL – III – FUNDACIÓN GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER MAMA
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, QY; Nobre, A; Pineiro, P; Berciano-Guerrero, MA; Alba, E; Cobo, M; Lauschke, VM; Barragan, I – 2020
The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response
Sanchez-Alcoholado, L; Ramos-Molina, B; Otero, A; Laborda-Illanes, A; Ordonez, R; Medina, JA; Gomez-Millan, J; Queipo-Ortuno, MI – 2020
Gut Microbiota-Mediated Inflammation and Gut Permeability in Patients with Obesity and Colorectal Cancer
Sanchez-Alcoholado, L; Ordonez, R; Otero, A; Plaza-Andrade, I; Laborda-Illanes, A; Medina, JA; Ramos-Molina, B; Gomez-Millan, J; Queipo-Ortuno, MI – 2020
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus
Isla, D; de Castro, J; Garcia-Campelo, R; Lianes, P; Felip, E; Garrido, P; Paz-Ares, L; Trigo, JM – 2020
Inertial Sensors Embedded in Smartphones as a Tool for Fatigue Assessment Based on Acceleration in Survivors of Breast Cancer.
Cuesta-Vargas, AI; Pajares, B; Trinidad-Fernandez, M; Alba, E; Roldan-Jimenez, C – 2020
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
Feliu, J; Garcia-Carbonero, R; Capdevila, J; Guasch, I; Alonso-Orduna, V; Lopez, C; Garcia-Alfonso, P; Castanon, C; Sevilla, I; Cerezo, L; Conill, C; Quintana-Angel, B; Sanchez, ME; Ghanem, I; Martin-Richard, M; Lopez-Gomez, M; Leon, A; Caro, M; Fernandez, T; Maurel, J – 2020
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
van Brummelen, EMJ; Levchenko, E; Domine, M; Fennell, DA; Kindler, HL; Viteri, S; Gadgeel, S; Lopez, PG; Kostorov, V; Morgensztern, D; Orlov, S; Zauderer, MG; Vansteenkiste, JF; Baker-Neblett, K; Vasquez, J; Wang, XW; Bellovin, DI; Schellens, JHM; Yan, L; Mitrica, I; DeYoung, MP; Trigo, J – 2020
Lung cancer symptoms at diagnosis: results of a nationwide registry study
Ruano-Ravina, A; Provencio, M; de Juan, VC; Carcereny, E; Moran, T; Rodriguez-Abreu, D; Lopez-Castro, R; Albite, EC; Guirado, M; Gonzalez, LG; Massuti, B; Granados, ALO; Blasco, A; Cobo, M; Garcia-Campelo, R; Bosch, J; Trigo, J; Juan, O; de la Rosa, CA; Domine, M; Sala, M; Oramas, J; Casal-Rubio, J; Cerezo, S – 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Subbiah, V; Paz-Ares, L; Besse, B; Moreno, V; Peters, S; Sala, MA; Lopez-Vilarino, JA; Fernandez, C; Kahatt, C; Alfaro, V; Siguero, M; Zeaiter, A; Zaman, K; Lopez, R; Ponce, S; Boni, V; Arrondeau, J; Delord, JP; Martinez, M; Wannesson, L; Anton, A; Valdivia, J; Awada, A; Kristeleit, R; Olmedo, ME; Rubio, MJ; Sarantopoulos, J; Chawla, SP; Mosquera-Martinez, J; D’Arcangelo, M; Santoro, A; Villalobos, VM; Sands, J; Trigo, J – 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Trigo, J; Subbiah, V; Besse, B; Moreno, V; Lopez, R; Sala, MA; Peters, S; Ponce, S; Fernandez, C; Alfaro, V; Gomez, J; Kahatt, C; Zeaiter, A; Zaman, K; Boni, V; Arrondeau, J; Martinez, M; Delord, JP; Awada, A; Kristeleit, R; Olmedo, ME; Wannesson, L; Valdivia, J; Rubio, MJ; Anton, A; Sarantopoulos, J; Chawla, SP; Mosquera-Martinez, J; D’Arcangelo, M; Santoro, A; Villalobos, VM; Sands, J; Paz-Ares, L – 2020
AR-V7as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A HypotheticalCost-SavingAnalysis
Pacheco-Orozco, RA; Montealegre-Paez, L; Cayol, F; Martinez-Gregorio, H; Oliver, J; Frecha, C; Vaca-Paniagua, F; Perdomo, S – 2020
Measurement of Serum Testosterone in Nondiabetic Young Obese Men: Comparison of Direct Immunoassay to Liquid Chromatography-Tandem Mass Spectrometry
Martinez-Escribano, A; Maroto-Garcia, J; Ruiz-Galdon, M; Barrios-Rodriguez, R; Alvarez-Millan, JJ; Cabezas-Sanchez, P; Plaza-Andrades, I; Molina-Vega, M; Tinahones, FJ; Queipo-Ortuno, MI; Fernandez-Garcia, JC – 2020
Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment
Laborda-Illanes, A; Sanchez-Alcoholado, L; Dominguez-Recio, ME; Jimenez-Rodriguez, B; Lavado, R; Comino-Mendez, I; Alba, E; Queipo-Ortuno, MI – 2020
Microbial Signature in Adipose Tissue of Crohn’s Disease Patients
Serena, C; Queipo-Ortuno, M; Millan, M; Sanchez-Alcoholado, L; Caro, A; Espina, B; Menacho, M; Bautista, M; Monfort-Ferre, D; Terron-Puig, M; Nunez-Roa, C; Maymo-Masip, E; Rodriguez, MM; Tinahones, FJ; Espin, E; Marti, M; Fernandez-Veledo, S; Vendrell, J – 2020
Challenges and achievements of liquid biopsy technologies employed in early breast cancer
Alba-Bernal, A; Lavado-Valenzuela, R; Dominguez-Recio, ME; Jimenez-Rodriguez, B; Queipo-Ortuno, MI; Alba, E; Comino-Mendez, I – 2020
Ocular surface characterization after allogeneic stem cell transplantation: A prospective study in a referral center,
Alba-Linero, C; de Mora, MRC; Valenzuela, RL; Cascon, MJP; Cerezo, ARM; Perez, MA; Recio, LV; Aragones, JMJ; Campos, JMG – 2020
Characterization of the Human Exposome by a Comprehensive and Quantitative Large-Scale Multianalyte Metabolomics Platform
Gonzalez-Dominguez, R; Jauregui, O; Queipo-Ortuno, MI; Andres-Lacueva, C – 2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
Andre, T; Shiu, KK; Kim, TW; Jensen, BV; Jensen, LH; Punt, C; Smith, D; Garcia-Carbonero, R; Benavides, M; Gibbs, P; de la Fouchardiere, C; Rivera, F; Elez, E; Bendell, J; Le, DT; Yoshino, T; Van Cutsem, E; Yang, P; Farooqui, MZH; Marinello, P; Diaz, LA – 2020
Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic
Rojas-Jimenez, E; Mejia-Gomez, JC; Diaz-Velasquez, C; Quezada-Urban, R; Gregorio, HM; Vallejo-Lecuona, F; de la Cruz-montoya, A; Reyes, FIP; Perez-Sanchez, VM; Maldonado-Martinez, HA; Robles-Estrada, M; Bargallo-Rocha, E; Cabrera-Galeana, P; Ramos-Ramirez, M; Chirino, YI; Herrera, LA; Terrazas, LI; Oliver, J; Frecha, C; Perdomo, S; Vaca-Paniagua, F – 2020
Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results
Carrato, A; Vieitez, JM; Benavides, M; Rodriguez-Garrote, M; Castillo, A; Ogalla, GD; Bermejo, LG; de Mena, IR; Guillen-Ponce, C; Aranda, E – 2020
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Members
-
Researcher in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
-
Investigador/a SéniorSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigador/a Asistencial Colaborador/aSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigador/a posdoctorales y/o juniorSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigadores/as predoctorales y/o formaciónSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Technical staffSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.